CME Corner

Program Detail

Release Date: September-30-19
Credit Expiration Date: September-30-20


Flavia Castelino, M.D.

Director, Scleroderma Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Jane E. Dematte, MD MBA
Professor of Medicine
Northwestern University
Feinberg School of Medicine
Director, Interstitial Lung Disease Program
Division of Pulmonary and Critical Care Medicine
Chicago, IL

Mary Beth Scholand, MD
Associate Professor and Director of the Interstitial Lung Disease Program
University of Utah
Salt Lake City, UT

Credit Hours



Online Presentation

Program Description

Interstitial lung disease (ILD) is a frequent complication of the autoimmune disorder systemic sclerosis (SSc). SSc-ILD remains a challenging condition to identify, treat, and manage. Early identification of ILD in patients with SSc is critical so that treatment can be initiated as soon as possible. However, utilization of optimal screening and diagnosis strategies is low among healthcare providers. Treatment decisions also represent a significant clinical challenge; a lack of guidance and effective treatments results in suboptimal practice and gaps in knowledge among providers. While new agents are on the horizon, dissemination of clinical trial data and uptake of new agents may be delayed. Monitoring of SSc-ILD patients is equally difficult, and research suggests suboptimal practice related to this aspect of care. Finally, poor patient-provider communication amplifies these challenges and contributes to patient anxiety.

Program Developer/Facilitator


Target Audience

Rheumatologists, pulmonologists, dermatologists, and other healthcare professionals who may encounter and/or treat patients with SSc-ILD.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss the epidemiology of ILD in patients with systemic sclerosis.
  2. Describe the screening and diagnostic evaluation of patients with SSc for ILD.
  3. Examine management options for ILD in patients with SSc.
  4. Review how to monitor progression of ILD and treatment response in SSc-ILD.
  5. Develop strategies to improve clinician communication with patients with SSc-ILD about their disease.


All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.

Dr. Castelino discloses the following:
Consultant: Boehringer-Ingelheim
Grants/Research Support: Scleroderma Research Foundation

Dr. Dematte discloses the following:
Advisory Board Membership: Boehringer-Ingelheim
Honorarium Recipient: Boehringer-Ingelheim

Dr. Scholand discloses the following:
Speaker Bureau: Boehringer-Ingelheim, Genentech
Advisory Board Membership: Boehringer-Ingelheim, Genentech, Veracyte

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals.

Certificate Fee



© 2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Purdue University, or Novartis Pharmaceuticals Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu